ENGLEWOOD, Colo., March 12,
2019 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI),
an innovative medical technology company specializing in the
manufacture and sale of non-invasive medical devices for pain
management, stroke rehabilitation, cardiac monitoring and
neurological diagnostics, announced today that it has signed
an addendum to its corporate headquarters building lease expanding
the footprint to 63,000 square feet, a 50% increase.
Thomas Sandgaard, CEO said: "Our
order and revenue growth has put pressure on expanding our
corporate headquarters and we are fortunate to have a Right of
First Refusal to add additional space with our existing building.
We moved in a year ago and already in need of more square footage
due to expanding shipments and employee additions. We are well
prepared for future growth as we continue to add sales
representatives across the country at a rapid rate."
About Zynex, Inc.
Zynex, founded in 1996, markets and sells its own design of
electrotherapy medical devices used for pain management and
rehabilitation; and the company's proprietary NeuroMove device
designed to help recovery of stroke and spinal cord injury
patients. Zynex is also developing a new blood volume monitor for
use in hospitals and surgery centers. For additional information,
please visit: www.zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" or
projections and as such are subject to numerous risks and
uncertainties. The company makes no express or implied
representation or warranty as to the completeness of this
information or, in the case of projections, as to their
attainability or the accuracy and completeness of the assumptions
from which they are derived. Actual results may vary significantly
from the results expressed or implied in such statements. Factors
that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the
need to obtain FDA clearance and CE marking of new products, the
acceptance of new products as well as existing products by doctors
and hospitals, larger competitors with greater financial resources,
the need to keep pace with technological changes, our dependence on
the reimbursement for our products from health insurance companies,
our dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force and other risks
described in our filings with the Securities and Exchange
Commission including the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31,
2018 as well as Forms 10-Q, 8-K and 8-K/A, press releases and
the Company's website.
Contact:
Zynex, Inc.
(303) 703-4906
Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zynex-expands-corporate-headquarters-to-accommodate-growth-300810687.html
SOURCE Zynex